Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Fierce Pharma
Astellas lifts forecast as Vyloy surge counters trial miss
Alongside a recorded loss pinned on Vyloy's pancreatic cancer setback, Astellas also terminated ASP4396, a phase 1 KRAS G12D program.
Angus Liu
Feb 5, 2026 11:00am
GE HealthCare posts higher revenues amid turbulent tariffs
Feb 5, 2026 10:45am
Angitia raises $130M to advance bone-building bispecifics
Feb 5, 2026 10:17am
Fierce Pharma
Veradermics locks in $256M IPO, shares spike
Feb 5, 2026 10:01am
Fierce Pharma
FDA’s rare pediatric voucher program revived by funding bill
Feb 4, 2026 3:12pm
Medtronic steps up with CathWorks buyout
Feb 4, 2026 9:15am
